XML 36 R25.htm IDEA: XBRL DOCUMENT v3.25.3

Revenues (Tables)

9 Months Ended

Sep. 30, 2025

Revenue from Contract with Customer [Abstract]

Schedule of Disaggregation of Revenue by Product and by Geographic Area

Revenues were as follows (in millions):

						Three months ended September 30,
						2025																		2024
						U.S.						ROW						Total						U.S.						ROW						Total
Prolia						$	806					$	333					$	1,139					$	683					$	362					$	1,045
Repatha						442						352						794						281						286						567
ENBREL						574						6						580						817						8						825
Otezla						473						112						585						460						104						564
XGEVA						357						182						539						373						168						541
EVENITY						417						124						541						289						110						399
TEPEZZA						518						42						560						482						6						488
BLINCYTO						236						156						392						237						90						327
Nplate						333						124						457						345						111						456
KYPROLIS						225						134						359						238						140						378
Aranesp						103						254						357						105						232						337
TEZSPIRE(1)						377						—						377						269						—						269
KRYSTEXXA						320						—						320						310						—						310
Vectibix						162						122						284						132						150						282
Other products(2)						1,408						445						1,853						958						405						1,363
Total product sales(3)						$	6,751					$	2,386					9,137						$	5,979					$	2,172					8,151
Other revenues																		420																		352
Total revenues																		$	9,557																	$	8,503

						Nine months ended September 30,
						2025																		2024
						U.S.						ROW						Total						U.S.						ROW						Total
Prolia						$	2,271					$	1,089					$	3,360					$	2,110					$	1,099					$	3,209
Repatha						1,146						1,000						2,146						824						792						1,616
ENBREL						1,675						19						1,694						2,280						21						2,301
Otezla						1,328						312						1,640						1,185						317						1,502
XGEVA						1,064						573						1,637						1,138						526						1,664
EVENITY						1,132						369						1,501						806						326						1,132
TEPEZZA						1,349						97						1,446						1,379						12						1,391
BLINCYTO						779						367						1,146						555						280						835
Nplate						762						377						1,139						749						370						1,119
KYPROLIS						673						388						1,061						712						419						1,131
Aranesp						301						755						1,056						296						738						1,034
TEZSPIRE(1)						1,004						—						1,004						676						—						676
KRYSTEXXA						905						—						905						839						—						839
Vectibix						441						415						856						385						414						799
Other products(2)						3,907						1,283						5,190						2,858						1,204						4,062
Total product sales(3)						$	18,737					$	7,044					25,781						$	16,792					$	6,518					23,310
Other revenues																		1,104																		1,028
Total revenues																		$	26,885																	$	24,338

_______

(1)    TEZSPIRE is marketed by our collaborator AstraZeneca outside the United States.

(2)    Consists of product sales of our non-principal products.

(3)    Hedging gains and losses, which are included in product sales, were not material for the three and nine months ended September 30, 2025 and 2024.

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration